Back to top
more

Quest Diagnostics (DGX)

(Delayed Data from NYSE)

$137.38 USD

137.38
640,501

+1.04 (0.76%)

Updated May 3, 2024 03:59 PM ET

After-Market: $137.46 +0.08 (0.06%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.20%
2Buy18.04%
3Hold9.52%
4Sell5.20%
5Strong Sell2.60%
S&P50011.13%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

B Value C Growth C Momentum B VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 31% (77 out of 252)

Industry: Medical - Outpatient and Home Healthcare

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Zacks News

Henry Schein (HSIC) to Report Q1 Earnings: What's in Store?

by Zacks Equity Research

Henry Schein's (HSIC) medical business is expected to have gained from improved U.S. patient traffic to physician offices, ultimate care sites and ambulatory surgical centers.

Quest Diagnostics (DGX) to Post Q1 Earnings: What's in Store?

by Zacks Equity Research

Quest Diagnostics' (DGX) first-quarter 2023 results are likely to reflect an impressive performance in its non-COVID-19 base business amid inflationary pressure and labor challenges.

Align Technology (ALGN) to Post Q1 Earnings: What's in Store?

by Zacks Equity Research

Align Technology's (ALGN) first-quarter 2023 results are likely to witness impressive performance across its operating segments amid macroeconomic pressure.

Quest Diagnostics (DGX) Advances Access to Transplant Services

by Zacks Equity Research

Quest Diagnostics' (DGX) upgrade to advanced diagnostics and support services is likely to feature personalized patient access to service centers and mobile phlebotomists.

These 2 Medical Stocks Could Beat Earnings: Why They Should Be on Your Radar

by Zacks Equity Research

Investors looking for ways to find stocks that are set to beat quarterly earnings estimates should check out the Zacks Earnings ESP.

How to Boost Your Portfolio with Top Medical Stocks Set to Beat Earnings

by Zacks Equity Research

Investors looking for ways to find stocks that are set to beat quarterly earnings estimates should check out the Zacks Earnings ESP.

Quest Diagnostics (DGX) Upgraded to Buy: What Does It Mean for the Stock?

by Zacks Equity Research

Quest Diagnostics (DGX) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).

Reasons to Retain Quest Diagnostics (DGX) Stock for Now

by Zacks Equity Research

Investors are optimistic about Quest Diagnostics (DGX) on solid fourth-quarter 2022 performance and its strategies to accelerate growth.

Quest Diagnostics (DGX) Introduces New Post-COVID-19 Panels

by Zacks Equity Research

Quest Diagnostics' (DGX) latest panels provide consumers a deeper look into their health, helping to prepare them for meaningful discussions with their healthcare providers

Quest Diagnostics (DGX) Advances Transplant Testing Service

by Zacks Equity Research

These services by Quest Diagnostics (DGX) are available to recipients and living donors across the United States (excluding Alaska and Hawaii), broadening access for both donor and patient.

Quest Diagnostics (DGX) Acquires Northern Light Laboratory

by Zacks Equity Research

Quest Diagnostics (DGX) now offers professional laboratory management services for nine of Northern Light Health's hospital laboratories.

Why Investors Need to Take Advantage of These 2 Medical Stocks Now

by Zacks Equity Research

Investors looking for ways to find stocks that are set to beat quarterly earnings estimates should check out the Zacks Earnings ESP.

Quest Diagnostics (DGX) Updates Its Strategic Focus, LT Growth

by Zacks Equity Research

Quest Diagnostics (DGX) is building strong platforms to focus on high-growth areas like molecular genomics and oncology.

Ensign Group's (ENSG) Buyout Consolidates Colorado Presence

by Zacks Equity Research

The Ensign Group (ENSG) buys two skilled nursing facilities in Colorado, aiming to expand its portfolio of nursing homes in the state.

Are Investors Undervaluing Quest Diagnostics (DGX) Right Now?

by Zacks Equity Research

Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.

Reasons to Add Quest Diagnostics (DGX) Stock to Your Portfolio

by Zacks Equity Research

Investors continue to be optimistic about Quest Diagnostics (DGX) on its accelerated growth strategy and improvements in base volumes.

Quest Diagnostics (DGX) Base Business Growth Robust, Volume Up

by Zacks Equity Research

Quest Diagnostics (DGX) starts to benefit from incentives related to these value-based contracts, which help demonstrate the value of these strategic relationships.

Quest Diagnostics (DGX) New Pact to Boost Laboratory Services

by Zacks Equity Research

Quest Diagnostics' (DGX) recent agreement is intended to offer advanced and quality clinical laboratory services in the greater New York region and beyond.

Urmimala Biswas headshot

3 MedTech Stocks Likely to Beat Estimates This Earnings Season

by Urmimala Biswas

MedTech companies' results are likely to reflect base business recovery on a year-over-year basis. Let's see how EXAS, MDT and IART are poised ahead of their earnings releases.

Quest Diagnostics (DGX) Q4 Earnings Top Estimates, Margin Down

by Zacks Equity Research

Improvement within Quest Diagnostics' (DGX) legacy base business contributes to Q4 performance.

Quest Diagnostics (DGX) Beats Q4 Earnings and Revenue Estimates

by Zacks Equity Research

Quest Diagnostics (DGX) delivered earnings and revenue surprises of 4.21% and 3.56%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?

Indrajit Bandyopadhyay headshot

MedTech Stocks' Earnings to Watch on Feb 2: BDX, DGX & CNMD

by Indrajit Bandyopadhyay

Medical Device players are likely to have benefited from the reopening of economies and several efforts to combat staffing challenges. Let's see how BDX, DGX and CNMD are likely to fare this time.

Quest Diagnostics (DGX) to Report Q4 Earnings: What's in Store?

by Zacks Equity Research

Quest Diagnostics (DGX) ramps up investments to accelerate growth in the base business, particularly in advanced diagnostics and direct-to-consumer testing.

Abhinab Dasgupta headshot

Take the Zacks Approach to Beat the Market: Boeing, Halliburton, Starbucks in Focus

by Abhinab Dasgupta

Our time-tested methodologies were at work to help investors navigate the market well last week. Here are some of our key performance data from the past three months.

Is Quest Diagnostics (DGX) Stock Undervalued Right Now?

by Zacks Equity Research

Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.